Prime Medicine, Inc.
PRMENASDAQHealthcareBiotechnology
As of Oct 15, 2026 close
- Market cap
- $639.78M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $2.67$6.65
- Volume (live)
- -
- Avg. volume (3M)
- 4.32M
Prime Medicine (PRME) Stock Price & Financial Analysis
Prime Medicine Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $3.06 - $3.65 |
|---|---|
| 52-Week High | $6.65 |
| 52-Week Low | $2.67 |
| Open | $3.12 |
| Volume (last close) | 6.29M |
| Average Volume (3M) | 4.32M |
| Revenue (TTM) | 4.07M |
|---|---|
| Net Income (TTM) | -187.89M |
| Free Cash Flow (TTM) | -156.85M |
| EPS (TTM) | −$1.13 |
| Profit Margin | -4613.11% |
| Operating Margin | -4824.94% |
| Return on Equity (ROE) | -471.98% |
| Debt to Equity | 2.83 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 639.78M |
|---|---|
| Shares Outstanding | 177.22M |
| Price to Sales (P/S) | 157.08 |
| Price to Book (P/B) | 16.07 |
| EV/EBITDA | -3.83 |
| 50-Day MA | $3.31 |
|---|---|
| 200-Day MA | $3.48 |
| 1-Year Change | −37.76% |
Source: Market prices and company fundamentals. Data as of Oct 15, 2026. Data sources and methodology
Prime Medicine at a Glance
As of the Oct 15, 2026 close, Prime Medicine (PRME) has a market capitalization of $639.78M. The stock trades at 157.1× sales. Over the trailing twelve months it lost $187.89M on revenue of $4.07M and burned $156.85M of free cash flow. Revenue fell 17.9% year over year.
As of its latest reported balance sheet, it holds $47.45M in cash and securities against $112.48M of debt, a net debt position of $65.03M.
Prime Medicine does not currently pay a dividend.
The share price is down 37.8% over the past year. At $3.61 (the Oct 15, 2026 close) it sits within its 52-week range of $2.67 to $6.65, above its 200-day moving average of $3.48.
Based on 10 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $7.86, 117.7% above the Oct 15, 2026 close.
Frequently Asked Questions About Prime Medicine
What is the current stock price for PRME?
As of the Oct 15, 2026 close, PRME stock trades at $3.61. The 52-week range is $2.67–$6.65, with a day range of $3.06–$3.65.
What is the P/E ratio for PRME?
The P/E ratio (Price-to-Earnings) for PRME is shown in the Key Statistics section. This valuation metric helps compare Prime Medicine, Inc. to industry peers.
Does PRME pay dividends?
Prime Medicine does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for PRME?
Based on ratings from 10 professional analysts over the last 90 days, the consensus for PRME is Buy. The average 12-month price target is $7.86, a 117.7% upside from the Oct 15, 2026 close of $3.61.
What is the market cap of PRME?
As of the Oct 15, 2026 close, Prime Medicine's market capitalization is $639.8M, classifying it as a small-cap company. Prime Medicine operates in the Healthcare sector within the Biotechnology industry.